Wide-ranging neurocognitive assessment is an integral component of controlled clinical trials of candidate antipsychotic treatments. However, manual administration of large neurocognitive test batteries is inefficient, error prone, and does not meet the needs for standardization across multiple sites. ? ? The project objective is to develop an advanced, wide spectrum computerized neurocognitive assessment system that will provide a single, unified platform for comprehensive administration and management of various protocols sufficient to meet the requirements of a minimum of 75% of controlled clinical trials as well as related research protocols. The CAES will introduce an unprecedented range of content, functionality and utility integration. Advantages include: (a) increased data quality through standardized multimedia-based administration; (b) integral multimedia-based examiner training for all tests; (c) automated project reporting and documentation; (d) automated patient tracking and scheduling; (e) automated protocol compliance; (f) reduced examiner requirements and errors; (g) comprehensive multilingual support; (h) automatic generation and tracking of CRFs; (i) automated electronic database transfer and (j) correspondingly reduced costs. The computer platform is uniquely suited to assessment of impaired subjects due to its interactive, dual-display and control architecture that integrates a human examiner, enabling precise control of every step of the administration process for any test. An examiner can score verbal report and overt behavioral performance, a capability not available in single-display systems. To ensure relevance of the assessment instrument battery as well as system functions for application in clinical trials, system development will be guided by a steering committee of recognized authorities in the field of schizophrenia research, including members of the NIMH-sponsored CATIE (Clinical Antipsychotic Trials in Intervention Effectiveness) consortium. The technical utility, concurrent validity and acceptability of the CAES test instruments and examiner training module will first be examined in a preliminary study (Year 1} and then in a multicenter study (Year 2). ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
3R44MH068077-02A1S1
Application #
7251866
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Light, Enid
Project Start
2003-09-26
Project End
2007-08-31
Budget Start
2005-09-30
Budget End
2006-08-31
Support Year
2
Fiscal Year
2006
Total Cost
$172,944
Indirect Cost
Name
Neurocomp Systems, Inc.
Department
Type
DUNS #
031270205
City
Irvine
State
CA
Country
United States
Zip Code
92704